Cendi - Endocrinologia e Diabetes

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Type 1 diabetes3 trials
• Obesity2 trials
• Type 2 diabetes2 trials

Phase

• Phase 35 trials

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company5 trials

Running trials

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Eli Lilly and Company· Source

  Contact: Nelson Rassi (principal investigator)

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

  Contact: Nelson Rassi (principal investigator)

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

  Contact: Nelson Rassi (principal investigator)

• Active, not recruiting

  A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

  NCT06962280· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 1 diabetes2 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source